# Jasper Therapeutics (JSPR) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/JSPR
## Company Profile
- Ticker: JSPR
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Stem Cells
## Stock Data
- Close: 0.4956 USD
- Market cap: 15434646.3147 USD
- Last updated: 2026-10-13
## Business Overview
### Immune-Mediated Disease Company
Jasper Therapeutics is developing therapies for immune-mediated diseases following its combination with Kira Pharmaceuticals. The expanded portfolio includes programs targeting complement biology, pathogenic immune cells, and mast-cell-driven disorders.
### KP-104 Dual Complement Inhibitor
KP-104, or vensobafusp alfa, is a bifunctional molecule designed to inhibit both the alternative and terminal complement pathways. It is Phase 2/3-ready in paroxysmal nocturnal hemoglobinuria and is also being evaluated in a Phase 2 basket study across rare complement-mediated renal diseases.
### Briquilimab
Briquilimab is an anti-KIT monoclonal antibody designed to deplete mast cells and hematopoietic stem cells. Jasper is developing the candidate for mast-cell-driven diseases, including chronic urticarias and allergic asthma, and as a conditioning agent for stem-cell transplantation.
### KP-701
KP-701 is a dual-acting CD79B and CD32B antibody intended to suppress pathogenic B-cell signaling in autoantibody-mediated disorders. The program is advancing through preclinical development toward an initial clinical application.
## Why The Stock Is Moving

As of Oct 13, 2026, JSPR closed down 10.7% at $0.4956. No new same-company headline was identified in the current news window.

## Future Catalysts

- Stage 1 interim data from the Phase 2 KP-104 renal-disease basket study in Q4 2026.
- Announcement of the briquilimab regulatory path following planned pre-BLA engagement in Q1 2027.
- CTA or IND submission for KP-701 in Q1 2027.
- FDA end-of-Phase 2 meeting and announcement of next development steps for KP-104 in PNH in the first half of 2027.

## Recent News
- 2026-10-07 12:00 EST — [Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants](https://biopharmsignal.com/news/JSPR/jasper-therapeutics-announces-commencement-of-an-offer-to-purchase-outstanding-w-377618a3) — Source: Jasper Therapeutics
- 2026-09-15 20:05 EST — [Jasper Therapeutics Announces Key Regulatory and Clinical Appointments](https://biopharmsignal.com/news/JSPR/jasper-therapeutics-announces-key-regulatory-and-clinical-appointments-840f0f28) — Source: Jasper Therapeutics
- 2026-09-09 12:00 EST — [Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference](https://biopharmsignal.com/news/JSPR/jasper-therapeutics-to-present-at-the-h-c-wainwright-28th-annual-global-investme-59ca56a8) — Source: Jasper Therapeutics
- 2026-08-14 15:00 EST — [Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/JSPR/jasper-therapeutics-reports-second-quarter-2026-financial-results-and-provides-c-629b3111) — Source: Jasper Therapeutics
- 2026-07-16 21:15 EST — [Jasper Therapeutics Announces Merger with Kira Pharmaceuticals](https://biopharmsignal.com/news/JSPR/jasper-therapeutics-announces-merger-with-kira-pharmaceuticals-a3889d24) — Source: Jasper Therapeutics